Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. (Q43680378)

25 November 2017

title

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. (English)

1 reference

25 November 2017

1 reference

1

1 reference

25 November 2017

2

1 reference

25 November 2017

Paolo Giovanni Casali

8

1 reference

25 November 2017

7

Silvana Pilotti

1 reference

25 November 2017

Francesca Miselli

3

1 reference

25 November 2017

Maria Stefania Lagonigro

4

1 reference

25 November 2017

Paola Coco

5

1 reference

25 November 2017

Antonella Messina

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

25 November 2017

1 reference

25 November 2017

volume

245

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

341-346

1 reference

PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.

25 November 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Is there a role for surgery in patients with "unresectable" cKIT gastrointestinal stromal tumors treated with imatinib mesylate?

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1877023

Diagnosis of gastrointestinal stromal tumors: A consensus approach

29 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17435538

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/01.SLA.0000242710.36384.1B

1 reference

25 November 2017

0 references

1 reference